Clinical trial · people
Setmelanotide: mean BMI fell 18% at 52 weeks in ages 2-5 (VENTURE)
Checked against the paper Clinical trialPublished by PepVault
The takeaway
This is the first trial of setmelanotide in children under 6, and it found BMI drops and less hunger in this small group, with larger drops in POMC or LEPR deficiency than in BBS.
- Kind
- Clinical trial
- Studied in
- People
- Number studied
- 12
- Published
- 2025
- Journal
- Lancet Diabetes Endocrinol
What they tested
The team tested whether daily setmelanotide shots work and are safe in very young children, aged 2-5, with obesity and extreme hunger caused by POMC or LEPR deficiency or Bardet-Biedl syndrome (BBS).
How the study was done
An open-label phase 3 trial, with no comparison group, at six sites in the USA, the UK, Spain, and Australia. It enrolled 12 children aged 2-5 (seven with POMC or LEPR deficiency, five with BBS), who took setmelanotide under the skin once a day for 52 weeks, with the dose stepped up every 2 weeks.

What they found
At week 52, 10 (83%) of the 12 children had a drop of 0.2 points or more in BMI Z score, a score that compares a child's BMI with others of the same age and sex. On average, BMI changed by -18% (SD 13) overall: -26% (SD 11) in children with POMC or LEPR deficiency and -10% (SD 9) in children with BBS. Of caregivers, 91% said the child was less hungry than at the start. All side effects were mild or moderate, most often skin darkening, vomiting, colds, upper airway infections, and injection site reactions, and there were no serious side effects.
What it doesn’t show
This was a small, 1-year trial with no placebo or comparison group, and everyone knew they were getting the drug. It only included children with these specific genetic conditions, and it was funded by Rhythm Pharmaceuticals.
The paper
Argente et al. Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol. 2025.
The compound
More studies on Setmelanotide
- Setmelanotide: injection-site reactions in 96% in pooled trialsMeta-analysis · people · 2026
- Setmelanotide: 16.5% BMI drop at 52 weeks in hypothalamic obesityRandomized trial · people · 2026
- Setmelanotide: patients reported less hunger, more energy in TRANSCENDClinical trial · people · 2026
- Setmelanotide: 15% mean BMI drop at 16 weeks in hypothalamic obesityClinical trial · people · 2024
- Setmelanotide: quality of life rose after 52 weeks in Bardet-BiedlClinical trial · people · 2023
- Setmelanotide: 80% (POMC) and 45% (LEPR) lost at least 10% weightClinical trial · people · 2020
- Every study on Setmelanotide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.